Anthem Biosciences shares list at 27% premium over IPO price on NSE; should you buy, sell or hold?

Anthem Biosciences IPO shares listed at 27% premium over IPO price on NSE.

Anthem Biosciences shares listed on the stock exchanges on Monday with a premium of about 27 percent over it's initial public offer (IPO) price. The Rs 3,395-crore public offer was priced in the band of Rs 540-570 per share, and received strong investor interest with about 64 times subscription during the offer period from July 14 to 16.

Shares of Anthem Biosciences were listed at Rs 723.05 per share on the NSE, a premium of 26.85 percent.

On the BSE, the shares were listed at Rs 723.10 apiece, a premium of 26.86 percent. The total market capitalization post listing of the shares of the company stood at Rs 40,610.02 crore. The company had earlier raised Rs 1,016-crore from anchor investors.

The listing of the shares of the company was on the stock exchanges on July 21 was below than the expectations in the grey market, which had price in about 31 percent listing gains.

Check All IPO News

Anthem Biosciences shares: Should you buy, sell or hold?

Naren Agarwal, CEO and Partner, Wealth1, noted "that what sets Anthem apart is its unparalleled end‑to‑end CRDMO platform—spanning fermentation APIs, ADCs, peptides, oligonucleotides, and RNA therapeutics—backed by the country’s largest fermentation capacity at 182 kL and a client base of over 675 global partners in 44 countries.

"With revenue growing at a 25–30% CAGR, EBITDA margins nearing 37%, and ROCE in the high teens, the company clearly exhibits strong operational leverage. And because this is a pure OFS, there’s no dilution pressure—Anthem starts trading with a clean sheet. Should the listing match grey market projections and Q2 earnings maintain their momentum, Anthem is poised to emerge as the flagship stock heralding India’s biotech resurgence," he added.

Narendra Solanki, Head – Fundamental Research (Investment Services), Anand Rathi Shares and Stock Brokers, said, "On valuation, based on annualised FY25 earnings, the company is seeking a PE of 70.6 times. The post-issue market capitalisation stands at Rs 31,867 crore. We believe the issue is fairly priced, supported by strong growth, industry-leading margins, and steady profitability. Investors allotted shares may consider holding them for long-term growth."

Anthem Biosciences Shares: Experts suggest this post-listing strategy

Anthem Biosciences is a tech-driven, integrated service provider in drug discovery, development, and manufacturing for both small molecules and biologics. The company is among the few players offering end-to-end services across the drug lifecycle, catering to the CRO and CRDMO segments in the pharmaceutical and biotechnology industries.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.